{
  "guideline": {
    "id": "PA166229081",
    "name": "Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1",
    "source": "CPIC",
    "version": 5,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166229081",
    "relatedChemicals": [
      {
        "id": "PA164744372",
        "name": "amikacin",
        "symbol": null
      },
      {
        "id": "PA449753",
        "name": "gentamicin",
        "symbol": null
      },
      {
        "id": "PA450137",
        "name": "kanamycin",
        "symbol": null
      },
      {
        "id": "PA164784023",
        "name": "paromomycin",
        "symbol": null
      },
      {
        "id": "PA166228921",
        "name": "plazomicin",
        "symbol": null
      },
      {
        "id": "PA451512",
        "name": "streptomycin",
        "symbol": null
      },
      {
        "id": "PA451704",
        "name": "tobramycin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA31274",
        "name": "mitochondrially encoded 12S RNA",
        "symbol": "MT-RNR1"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166296970",
      "name": "Recommendation PA166296970",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450137",
          "name": "kanamycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059572,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296974",
      "name": "Recommendation PA166296974",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA166228921",
          "name": "plazomicin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059576,
        "html": "<p>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</p>\n"
      },
      "implications": [
        "MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166296965",
      "name": "Recommendation PA166296965",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449753",
          "name": "gentamicin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059567,
        "html": "<p>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</p>\n"
      },
      "implications": [
        "MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166296978",
      "name": "Recommendation PA166296978",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451512",
          "name": "streptomycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059580,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296969",
      "name": "Recommendation PA166296969",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450137",
          "name": "kanamycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059571,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296982",
      "name": "Recommendation PA166296982",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451704",
          "name": "tobramycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059584,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296973",
      "name": "Recommendation PA166296973",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA164784023",
          "name": "paromomycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059575,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296964",
      "name": "Recommendation PA166296964",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA164744372",
          "name": "amikacin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059566,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296977",
      "name": "Recommendation PA166296977",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451512",
          "name": "streptomycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059579,
        "html": "<p>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</p>\n"
      },
      "implications": [
        "MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166296968",
      "name": "Recommendation PA166296968",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450137",
          "name": "kanamycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059570,
        "html": "<p>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</p>\n"
      },
      "implications": [
        "MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166296981",
      "name": "Recommendation PA166296981",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451704",
          "name": "tobramycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059583,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296972",
      "name": "Recommendation PA166296972",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164784023",
          "name": "paromomycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059574,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296963",
      "name": "Recommendation PA166296963",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164744372",
          "name": "amikacin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059565,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296976",
      "name": "Recommendation PA166296976",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA166228921",
          "name": "plazomicin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059578,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296967",
      "name": "Recommendation PA166296967",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449753",
          "name": "gentamicin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059569,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296980",
      "name": "Recommendation PA166296980",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451704",
          "name": "tobramycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059582,
        "html": "<p>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</p>\n"
      },
      "implications": [
        "MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166296971",
      "name": "Recommendation PA166296971",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164784023",
          "name": "paromomycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059573,
        "html": "<p>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</p>\n"
      },
      "implications": [
        "MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166296975",
      "name": "Recommendation PA166296975",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA166228921",
          "name": "plazomicin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059577,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296962",
      "name": "Recommendation PA166296962",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164744372",
          "name": "amikacin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059564,
        "html": "<p>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</p>\n"
      },
      "implications": [
        "MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166296966",
      "name": "Recommendation PA166296966",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449753",
          "name": "gentamicin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059568,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166296979",
      "name": "Recommendation PA166296979",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451512",
          "name": "streptomycin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059581,
        "html": "<p>Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.</p>\n"
      },
      "implications": [
        "MT-RNR1: Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."
      ],
      "lookupKey": {
        "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": "34032273",
      "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype.",
      "authors": [
        "McDermott John Henry",
        "Wolf Joshua",
        "Hoshitsuki Keito",
        "Huddart Rachel",
        "Caudle Kelly E",
        "Whirl-Carrillo Michelle",
        "Steyger Peter S",
        "Smith Richard J H",
        "Cody Neal",
        "Rodriguez-Antona Cristina",
        "Klein Teri E",
        "Newman William G"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613315"
    }
  ],
  "version": "2024-02-29-20-19"
}